Literature DB >> 20178773

CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9.

Takeshi Shimosato1, Megumi Fujimoto, Masanori Tohno, Takashi Sato, Mariko Tateo, Hajime Otani, Haruki Kitazawa.   

Abstract

We previously reported the strong immunostimulatory effects of a CpG oligodeoxynucleotide (ODN), designated MsST, from the lacZ gene of Streptococcus (S.) thermophilus ATCC19258. Here we show that 24h of stimulation with MsST in mouse splenocytes and peritoneal macrophages strongly induces expression of interleukin (IL)-33, a cytokine in the IL-1 superfamily. Other IL-1 superfamily members, including IL-1alpha, IL-1beta and IL-18, are down-regulated after 24h of stimulation of MsST. We also found that MsST-induced IL-33 mRNA expression is inhibited by the suppressive ODN A151, which can inhibit Toll-like receptor 9 (TLR9)-mediated responses. This is the first report to show that IL-33 can be induced by CpG ODNs. The strong induction of IL-33 by MsST suggests that it may be a potential therapeutic ODN for the treatment of inflammatory disease. The presence of a strong CpG ODN in S. thermophilus also suggests that the bacterium may be a good candidate as a starter culture for the development of new physiologically functional foods. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178773     DOI: 10.1016/j.bbrc.2010.02.110

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

2.  Expression of a biologically active GFP-α(S1)-casein fusion protein in Lactococcus lactis.

Authors:  Suguru Shigemori; Shinichi Yonekura; Takashi Sato; Maya Nakanishi; Hajime Otani; Takeshi Shimosato
Journal:  Curr Microbiol       Date:  2012-03-22       Impact factor: 2.188

3.  Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice.

Authors:  Yeqin Wang; Yoshinari Yamamoto; Suguru Shigemori; Takafumi Watanabe; Kazushi Oshiro; Xinyu Wang; Pengfei Wang; Takashi Sato; Shinichi Yonekura; Sachi Tanaka; Haruki Kitazawa; Takeshi Shimosato
Journal:  Mol Ther       Date:  2014-12-15       Impact factor: 11.454

Review 4.  Use of nanoparticles to deliver immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman; Takashi Sato; Takeshi Shimosato
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-12-12

5.  Porphyromonas gingivalis Gingipain-Dependently Enhances IL-33 Production in Human Gingival Epithelial Cells.

Authors:  Hiroyuki Tada; Takashi Matsuyama; Takashi Nishioka; Makoto Hagiwara; Yusuke Kiyoura; Hidetoshi Shimauchi; Kenji Matsushita
Journal:  PLoS One       Date:  2016-04-08       Impact factor: 3.240

Review 6.  Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases.

Authors:  Suguru Shigemori; Takeshi Shimosato
Journal:  Front Immunol       Date:  2017-01-25       Impact factor: 7.561

7.  Free Feeding of CpG-Oligodeoxynucleotide Particles Prophylactically Attenuates Allergic Airway Inflammation and Hyperresponsiveness in Mice.

Authors:  Takuma Okajima; Suguru Shigemori; Fu Namai; Tasuku Ogita; Takashi Sato; Takeshi Shimosato
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

8.  Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression.

Authors:  Yusuke Ito; Suguru Shigemori; Takashi Sato; Tomoyuki Shimazu; Konomi Hatano; Hajime Otani; Haruki Kitazawa; Takeshi Shimosato
Journal:  FEBS Open Bio       Date:  2012-11-12       Impact factor: 2.693

9.  Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production.

Authors:  Shireen Nigar; Yoshinari Yamamoto; Takuma Okajima; Suguru Shigemori; Takashi Sato; Tasuku Ogita; Takeshi Shimosato
Journal:  BMC Immunol       Date:  2017-10-04       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.